SCHEMBL379387

SCHEMBL379387

c1ccc(-c2csc3ccnc(NCc4ccccn4)c23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.69
NOD1 Q9Y239 2/20 0.69
MAPK1 P28482 1/20 0.69
PIP4K2C Q8TBX8 1/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KCNA5 P22460 9/20 0.49
KCNH2 Q12809 8/20 0.49
JAK2 O60674 2/20 0.49
CDK2 P24941 2/20 0.49
TYK2 P29597 2/20 0.49
GSK3B P49841 2/20 0.49
JAK3 P52333 2/20 0.49
BTK Q06187 2/20 0.49
AURKB Q96GD4 2/20 0.49
IRAK4 Q9NWZ3 2/20 0.49
IGF1R P08069 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379865 0.86 ESR1 (0.55) TNFNOD1MAPK1PIP4K2CALDH1A1
SCHEMBL379503 0.83 TNF (0.50) TNFNOD1MAPK1PIP4K2CALDH1A1
SCHEMBL380011 0.81 UTS2R (0.53) TNFNOD1MAPK1ALDH1A1POLB
SCHEMBL2369019 0.81 MAPK1 (1.00) TNFNOD1MAPK1PIP4K2CALDH1A1
SCHEMBL379504 0.81 TNF (0.47) TNFNOD1MAPK1PIP4K2CALDH1A1
SCHEMBL379745 0.81 EED (0.49) TNFNOD1MAPK1ALDH1A1POLB
SCHEMBL4946829 0.80 PDE11A (0.49) TNFNOD1MAPK1ALDH1A1L3MBTL1
SCHEMBL379757 0.78 CCNC (0.47) TNFNOD1MAPK1L3MBTL1AURKB
SCHEMBL379602 0.78 PDE11A (0.47) TNFNOD1MAPK1ALDH1A1L3MBTL1
SCHEMBL2900101 0.78 TNF (0.69) TNFNOD1MAPK1PIP4K2CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 TNF 953/4885NOD1 141/4885MAPK1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.